LLC molecule idelasilib

Une particularité de la molécule est le fait que le nombre de globule blanc augmente rapidement au début du traitement et ensuite diminue lentement

 While all of this sound so positive, let's not forget that when Gilead ran a sensible and necessary trial combining its Syk inhibitor, GS-9973 and its better known PI3k inhibitor, idelalisib or Zydelig (click here for the abstract), they concluded: "Despite promising activity in CLL, the combination of GS-9973 and Idelalisib resulted in an unexpectedly high rate of pneumonitis and resulted in stopping dosing of the combination These data need to be considered when designing future investigations combining inhibitors of B cell receptor signaling."


http://www.cll-nhl.com/2013/06/cure-for-cll-nhl-or-just-better-control.html#.U7UvQ_l_vCs

By now, most patients are aware that in CLL, taking ibrutinib or idelalisib causes the white blood cells to go up and then slowly drift back down. Meanwhile the lymph nodes rapidly shrink and stay down. This is because the cells are merely getting shuffled around from a place where they are happy (lymph nodes and bone marrow) to the blood (where they are unhappy). Starting these drugs do not really eradicate a ton of cells right away though over time the cancer cells die off (death by neglect – a topic for another time).